Core Viewpoint - The company "Plant Doctor," with over 4,000 offline stores, has updated its prospectus and is moving forward with its IPO application after a previous halt due to outdated financial data. This marks a significant step towards its listing on the Shenzhen Stock Exchange [1]. Group 1: Business Model and Market Position - Plant Doctor employs a unique "single brand + all-channel" model, allowing it to stand out in the competitive beauty market. However, its heavy reliance on a distribution system and a single brand poses risks for its IPO journey [1][4]. - The company has established a strong presence with 4,269 offline stores as of June 2025, including 3,787 authorized dealer stores and 482 direct stores, ranking second in the beauty and body care sector in the "Top 100 Chain Enterprises" by the China Chain Store & Franchise Association [2]. - Plant Doctor emphasizes an experiential consumption model, combining product sales with in-store services, which enhances customer loyalty and repurchase intentions [2]. Group 2: Financial Performance - The financial data shows resilience in Plant Doctor's business model, with revenues of 2.117 billion yuan, 2.151 billion yuan, and 2.156 billion yuan from 2022 to 2024, and net profits increasing from 158 million yuan to 243 million yuan, reflecting a compound annual growth rate of 24% [2][3]. - As of June 30, 2025, the total assets amounted to 1.827 billion yuan, with net profits reaching 79 million yuan for the first half of 2025 [3]. Group 3: Challenges and Risks - The company faces challenges due to its high dependence on distributors, with over 60% of its revenue coming from them. This reliance poses potential risks to performance and brand image if any distributor faces issues [4]. - The single-brand strategy may limit growth potential as the company has not outlined plans for a multi-brand strategy, which could be a significant concern for future resilience [4]. - The rapid expansion of stores in 2023 is expected to face a bottleneck, with a projected net decrease in stores from 2024 to 2025 as the company shifts focus from quantity to quality [5]. Group 4: Future Plans and Innovations - Plant Doctor plans to raise approximately 998 million yuan through its IPO, focusing on marketing, brand building, headquarters and R&D center construction, production base upgrades, and information system enhancements [5]. - The company aims to optimize its offline store structure while enhancing its online presence through the "Xiaozhi Mall" private domain platform, which currently accounts for about 36% of its revenue [6]. - Continued collaboration with research institutions to deepen the exploration of high-altitude plant active ingredients is a priority, with 223 domestic and international patents held as of October 2025 [6].

Core Viewpoint - Beijing Plant Doctor Cosmetics Co., Ltd. is preparing for an IPO, with plans to issue up to 26.67 million shares, accounting for at least 25% of the total share capital post-issue [2] Financial Performance - The company projects revenue of 2.116 billion yuan, 2.150 billion yuan, and 2.155 billion yuan for the years 2022, 2023, and 2024 respectively, with net profits of 168 million yuan, 229 million yuan, and 242 million yuan for the same years [2] - The gross profit margins for the years 2022, 2023, and 2024 are expected to be 55.22%, 60.34%, and 58.90% respectively [2] Product Segmentation - The main revenue driver is the water and lotion cream segment, projected to generate 1.218 billion yuan in 2024, accounting for 56.52% of total revenue [3] - The essence and essence oil segment is expected to contribute 465 million yuan, representing 21.59% of total revenue, while face masks account for 16.28% [4] Sales Channels - The company employs a mixed sales model, primarily through distribution (66.72%) and supplemented by direct sales (33.28%) [8] - As of the end of 2024, the company operates 4,328 offline chain stores, with 3,830 authorized specialty stores and 498 direct stores [4] Market Position - Plant Doctor holds a 0.8% market share in the Chinese cosmetics market, ranking 9th among domestic brands [8] - The company’s revenue from the distribution model in 2024 is projected to be 1.366 billion yuan, accounting for 63.37% of total revenue [8] R&D and Competitive Edge - The company maintains a stable R&D expense ratio of 3% to 3.5% over the past three years, which is higher than several listed competitors [9] - Collaboration with the Kunming Institute of Botany has led to the development of a star product featuring Dendrobium orchid [9] Challenges - The company faces inventory pressure, with stock increasing from 192 million yuan at the end of 2023 to 223 million yuan at the end of 2024 [9] - Regulatory penalties on some stores due to violations have raised concerns about potential impacts on sales and performance [9]

Core Viewpoint - Beijing Plant Doctor Cosmetics Co., Ltd. has been accepted for IPO on the Shenzhen Stock Exchange, aiming to raise approximately 9.98 billion yuan, but faces challenges due to its heavy reliance on offline channels and declining online sales [2][3][4]. Group 1: IPO Details - The IPO application was accepted on June 27, 2025, with CITIC Securities as the sponsor [3]. - The company has been preparing for the IPO since 2023, indicating a long-term strategy to enter the public market [3]. Group 2: Business Model and Performance - Plant Doctor operates over 4,000 offline stores but has seen a decline in total store count from 4,664 to 4,328 in 2024, losing 336 stores [4][7]. - In 2024, online direct sales accounted for only 9.3% of total revenue, with the revenue from the "Xiaozhi Mall" declining from 843.9 million yuan in 2022 to 623.3 million yuan in 2024 [6][7]. - The company’s revenue growth has been minimal, increasing from 215.5 billion yuan to 215.57 billion yuan despite store optimization efforts [8]. Group 3: Financial Metrics - The comprehensive gross margin for 2024 was 58.9%, down from 60.35% in 2023, indicating pressure on profitability [9]. - The company’s inventory turnover efficiency decreased from 4.96 times in 2022 to 4.27 times in 2024, with inventory balance at 223 million yuan, representing 16% of current assets [10][11]. Group 4: Market Position and Competition - Plant Doctor's reliance on a high proportion of the distribution model (over 63% of revenue) has negatively impacted its gross margin compared to competitors like Proya and Marubi, which have higher margins due to a focus on direct sales [9]. - The online market share in China's cosmetics sector reached 52.45% in 2024, highlighting the risk of falling behind in digital transformation [8]. Group 5: Future Outlook - The company emphasizes the importance of private traffic and plans to integrate online and offline channels through its "Xiaozhi Mall" platform, although recent revenue trends suggest challenges in achieving this goal [12][14]. - The effectiveness of the private traffic strategy and its potential to drive sustainable revenue growth remains uncertain, requiring further data and strategic clarity from the company [14].

Core Viewpoint - The article discusses the IPO application of Beijing Plant Doctor Cosmetics Co., Ltd., highlighting its challenges in transitioning from a predominantly offline retail model to a more balanced online presence in the beauty industry [1][3]. IPO Details - Beijing Plant Doctor's IPO has been accepted by the Shenzhen Stock Exchange, with a projected fundraising amount of approximately 9.98 billion yuan [2]. - The company signed an IPO counseling agreement in 2023 and has only recently received acceptance from the exchange [2]. Business Model and Market Position - Plant Doctor operates over 4,000 offline stores and is considered a strong competitor for the title of "first beauty single brand stock" [3]. - The company has been criticized for its heavy reliance on offline channels, which has led to missed opportunities in the online market [3]. - In 2024, online direct sales accounted for only 9.3% of total revenue, indicating a significant lag behind competitors [6]. Revenue and Store Performance - The total number of stores decreased from 4,664 to 4,328 in 2024, with a net reduction of 336 stores [7]. - Despite the reduction in store count, revenue growth was minimal, increasing from 21.55 billion yuan to 21.557 billion yuan [7]. - The company has been optimizing its store network by closing underperforming locations, but this has not translated into revenue growth [7]. Online Sales and Competitor Comparison - Plant Doctor's online sales growth is significantly behind competitors like Proya, whose online direct sales accounted for over 75% of its revenue in 2024 [6]. - The company's online retail platform, "Xiaozhi Mall," has seen a decline in revenue from 839 million yuan in 2022 to 623 million yuan in 2024 [6]. Gross Margin and Distribution Model - The company primarily uses a distribution model, with over 63% of its revenue coming from this channel over the past three years, which has negatively impacted its gross margin [9]. - In 2024, Plant Doctor's overall gross margin was 58.9%, compared to Proya's 71.41% [9]. Inventory and Financial Metrics - As of May 31, 2025, 32 subsidiaries and stores have not obtained the necessary health permits for providing in-store services [10]. - The company's inventory turnover efficiency has declined from 4.96 times to 4.27 times from 2022 to 2024, with inventory balance at 223 million yuan [10]. - Key financial metrics include a current ratio of 2.21 and a debt-to-asset ratio of 44.97% [11]. Private Traffic Strategy - Plant Doctor emphasizes the importance of private traffic in its growth strategy, aiming to integrate offline and online channels through its private platform [13]. - The company claims that its private traffic team has developed standardized procedures that have generated significant revenue, although recent data shows a decline in revenue from its online platform [14].